Abstract
Jaboticaba (Plinia cauliflora), a Brazilian native fruit rich in bioactive compounds, exhibits potent anti-inflammatory and antioxidant properties. This pilot study evaluated the effects of jaboticaba peel supplementation on inflammatory and oxidative stress markers and uremic toxins among patients with chronic kidney disease (CKD) undergoing hemodialysis (HD) and explored its molecular effects in LLC-PK1 renal cells. A randomized, controlled clinical trial was conducted with 27 patients (55.0 [19.5] years, BMI 24.3 [3.8] kg/m2) on regular HD. Participants were allocated to receive the jaboticaba peel formulation (3.3 g/day, equivalent to ~667 mg of phenolic compounds) for 3 weeks or to routine treatment (control). Plasma levels of interleukin (IL)-1β and IL-17E (ELISA), lipid peroxidation (TBARS), protein carbonylation, and plasma levels of uremic were analyzed. LLC-PK1 cells were treated with 100 µL of jaboticaba peel formulation at different concentrations, and a panel of inflammatory genes was evaluated. While plasma IL-1β and IL-17E concentrations were increased in the control group, the jaboticaba group exhibited no significant changes, suggesting anti-inflammatory protection. Transcriptomic analysis revealed downregulation of key components of the TLR-MYD88-NF-κB-IL-1 axis after cell treatment. Additionally, cells treated with jaboticaba formulation (1.5%) showed reduced ROS levels, indicating antioxidant capacity. In conclusion, supplementation with jaboticaba peel attenuated the increase in pro-inflammatory markers in HD patients. These results suggest that jaboticaba peel holds promise as an adjuvant nutritional intervention for chronic inflammation in CKD.
Keywords:
Plinia cauliflora; chronic kidney disease; inflammation; jaboticaba; oxidative stress; renal dialysis.